NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

NurExone Biologic (TSXV: NRX) (FSE: J90)

Head of CMC ,Quality and Regulatory

Director of Research

VP Product Development

Vice President R&D

Director of Research and  Development

Director of Neuroscience

Project Manager

Research And Development Scientist

Research Scientist

Process Development Associate

Head of Bioprocess Development

Process Development Director

QC Director

Development Director

R&D Projects Manager

Research Assistant

R&D Student

SRE Team Leader

Operations Supervisor

Operations Team Member

Co-Founder and CEO

Translational science and Tech-transfer specialist

Head Of Research And Development

Senior Scientist

Senior Manager for Strategic R&D Projects

Founder / CEO

Chief Financial Officer

Lecturer in Bar-Ilan University

Chief Financial Officer and Director of Silenseed China (Subsidiary of Silenseed Ltd.)

Mergers and Acquisitions Manager

Senior Finance Director

Founder and Chief Executive Officer

VP Finance

Finance Manager

Financal Controller

Chief Executive Officer

Initiator and Head of the BioMed-MBA program

Partner at Hollyhigh International Capital; VP Technology Scouting, Innovation and Partnership WW

VP Technology Scouting, Innovation & Partnerships in Israel

Head of Research and Development

Senior Project Manager and Research Scientist

Co-Founder

PhD researcher

Visiting Ph.D. student

Research assistant

Laboratory assistant

Staff Sergeant, Full military service

Director of R&D

Bioanalytics Field Leader

Small Molecules Project Leader

Senior Assay Development Scientist

Teacher Assistant

QA Tester

Researcher

Development Scientist

Clinical Specialist in Advanced R&D

Lecturer

Teaching Assistant

Gmail

Google Apps

Google Tag Manager

Mobile Friendly

reCAPTCHA

Google Analytics

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.  We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

Emendo Biotherapeutics

Amazon SES

Atlassian Cloud

OneTrust

WordPress.org

Nginx

Bootstrap Framework

Pluristem researches, develops and commercializes cell therapies for the treatment of inflammation, ischemia and hematological disorders.

Nirit Drori-Carmi

Head of Bioprocess Development at NurExone Biologic (TSXV: NRX) (FSE: J90)

Nirit Drori-Carmi's Professional Contact Details

Nirit Drori-Carmi's Current Company Details

NurExone Biologic (TSXV: NRX) (FSE: J90)

Nirit Drori-Carmi's Work History and Education

Frequently Asked Questions about Nirit Drori-Carmi

What company does Nirit Drori-Carmi work for?

What is Nirit Drori-Carmi's role at NurExone Biologic (TSXV: NRX) (FSE: J90)?

What is Nirit Drori-Carmi's email address?

What is Nirit Drori-Carmi's business email address?

What is Nirit Drori-Carmi's HQ phone number?

What industry does Nirit Drori-Carmi work in?

Who are Nirit Drori-Carmi's colleagues?

Colleagues at NurExone Biologic (TSXV: NRX) (FSE: J90)

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?